Structure Therapeutics Inc (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company focused on developing oral small molecule drugs targeting G protein-coupled receptors (GPCRs). The company has not generated product revenue as of the 10-K filed February 26, 2026, and funds operations through equity financing, including ordinary shares traded on the Nasdaq Global Market in the form of American Depositary Shares. As of February 15, 2026, the company had 207,451,347 ordinary shares outstanding held in the form of ADSs, with a market value of approximately an undisclosed dollar amount based on a closing ADS price of $20.74 as of June 30, 2025. The filing excerpts do not disclose specific pipeline assets, partnership revenue, or competitive positioning with sufficient detail to characterize the company's product stage, therapeutic areas beyond GPCR targeting, or capital structure beyond its equity-financed, pre-revenue status.

Revenue model

The filing excerpts do not disclose a product revenue stream. Structure Therapeutics operates as a pre-revenue clinical-stage company financed through equity issuances.

Products and services

The filing excerpts do not provide sufficient detail on specific drug candidates, clinical trial stages, or therapeutic indications to characterize the product pipeline.

Customers and end markets

The filing excerpts do not identify customers or end markets. As a clinical-stage company, no commercial product sales are disclosed.

Value-chain role

Clinical-stage drug developer targeting GPCR biology with oral small molecule compounds.

Geographic exposure

The filing excerpts do not provide geographic revenue or operational detail beyond the company's listing on the Nasdaq Global Market and incorporation as a foreign private issuer filing ADSs.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: Innoviva Inc ANI Pharmaceuticals Inc Belite Bio Inc Filana Therapeutics Inc Collegium Pharmaceutical Inc CymaBay Therapeutics, Inc. Johnson & Johnson